MPM Bioimpact LLC Acquires 2,926,002 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

MPM Bioimpact LLC raised its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 51.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,567,896 shares of the company's stock after acquiring an additional 2,926,002 shares during the quarter. Compass Therapeutics comprises approximately 1.8% of MPM Bioimpact LLC's portfolio, making the stock its 27th biggest holding. MPM Bioimpact LLC owned approximately 6.23% of Compass Therapeutics worth $12,423,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. SG Americas Securities LLC boosted its stake in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after purchasing an additional 356,352 shares during the period. Catalina Capital Group LLC bought a new position in Compass Therapeutics in the 4th quarter worth about $71,000. Bleakley Financial Group LLC boosted its stake in Compass Therapeutics by 250.7% in the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock worth $58,000 after purchasing an additional 28,589 shares during the period. Finally, Rhumbline Advisers boosted its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock worth $187,000 after purchasing an additional 3,822 shares during the period. Hedge funds and other institutional investors own 68.43% of the company's stock.

Analyst Upgrades and Downgrades

CMPX has been the subject of several analyst reports. D. Boral Capital restated a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Jefferies Financial Group raised their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, February 10th. Guggenheim cut their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $13.13.

Compass Therapeutics Stock Up 3.9%

NASDAQ:CMPX traded up $0.08 during midday trading on Monday, hitting $2.18. The company had a trading volume of 272,362 shares, compared to its average volume of 1,713,439. Compass Therapeutics, Inc. has a 52-week low of $0.76 and a 52-week high of $4.08. The stock's fifty day moving average price is $1.94 and its 200-day moving average price is $2.11. The company has a market capitalization of $301.60 million, a PE ratio of -5.91 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). As a group, research analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Jonathan Anderman acquired 20,000 shares of the stock in a transaction on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is currently owned by corporate insiders.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.